We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GTC Biotherapeutics Obtains Licenses to Factor IX, Factor VIII and Fibrinogen
GTC Biotherapeutics Obtains Licenses to Factor IX, Factor VIII and Fibrinogen
December 5, 2007
GTC Biotherapeutics, Inc. has entered into a definitive agreement with ProGenetics, LLC, a private company based in Blacksburg, Virginia, to obtain an exclusive license to develop and commercialize ProGenetics’ recombinant human factor IX, recombinant human factor VIII, and recombinant human fibrinogen for North America, Europe and Japan. Yahoo! Finance
